Obesity market news — September 14, 2026
ObesityIntel: A correction, and it comes first because it is the most important change this week. In the August 31 and September 8 editions we listed three guided dates as open windows closing on September 30. Two of the three were not open. Structure Therapeutics announced on August 6, in the second-quarter release it filed with the SEC, that the first patients had been dosed in ACCOMPLISH-1 and ACCOMPLISH-2, the Phase 3 programme for aleniglipron. That was 25 days before we first described the start as pending. Viking Therapeutics never guided VANQUISH-2 topline to the third quarter of 2026; the Q3 date in its releases belongs to a separate Phase 1 maintenance-dosing study. VANQUISH-2 completed enrolment in the first quarter of 2026 with a 78-week treatment period, so its readout cannot arrive before 2027, and Viking's own words are that it looks forward to completing the VANQUISH studies in 2027. Both errors are ours. In both cases we relied on secondary reporting instead of the company's own release, and in the Viking case we did not do the arithmetic that would have shown the claim to be impossible. The Zealand and Roche entry was correct. We have changed our rule: a dated claim enters this log only from a primary source, and a trial timeline is checked against the trial's own duration before it is published.
Zealand Pharma (ZEAL), Viking Therapeutics (VKTX): What actually remains open, restated from primary sources. Zealand Pharma and Roche, in the half-year report of August 13, expect to initiate registrational Phase 3 trials of petrelintide monotherapy in the second half of 2026, alongside the Phase 2 ZYNERGY combination trial; as of September 14 neither start has been announced. Viking's own second-quarter release of July 29 gives three dates: results of the Phase 1 VK2735 maintenance-dosing study in the third quarter of 2026, initiation of oral VK2735 Phase 3 in the fourth quarter of 2026, and completion of the VANQUISH studies in 2027. The first of those closes in sixteen days. That is the corrected count: one Phase 3 start window, one Phase 1 readout, one Phase 3 initiation, and no Phase 3 topline of any kind in 2026.
Novo Nordisk (NVO): What changed: the Wegovy tablet went on sale in Germany on September 1, the first European Union country to receive it, at a list price of roughly 170 to 280 euros a month depending on dose. Against what: until then the oral product was sold in the United States, the United Kingdom and the United Arab Emirates. The European Commission's approval dates from July, not from this month; headlines on September 11 that read as a fresh EU approval were recycling that decision. The change in September is a launch, and Novo has said further European rollouts follow in late 2026. We did not carry the German launch in the September 8 edition and should have. Disclosure: the author holds shares in Novo Nordisk and Eli Lilly; the full statement is on the About page.
Clinical Nutrition / FDA FAERS: A dating note first: the study that produced this week's headlines about a deadly brain disorder was published in Clinical Nutrition in February 2026 and presented at AACE 2026. What happened this week was coverage, not a finding. The substance is still worth recording accurately. A pharmacovigilance analysis of the FDA Adverse Event Reporting System, covering safety reports on 195,979 people treated with GLP-1 receptor agonists between July 2014 and September 2024, identified fifteen cases of Wernicke encephalopathy, a thiamine-deficiency disorder that is treatable if caught early and can be fatal if not. The reporting odds ratio was 2.35 with a confidence interval of 1.38 to 4.01. Most cases involved semaglutide or tirzepatide, most emerged in 2023 and 2024, and most patients had severe vomiting or malnutrition beforehand. The authors state that the data cannot establish causation. Fifteen cases against roughly two hundred thousand reports is a signal for clinical awareness in patients with severe gastrointestinal symptoms, which is how the authors frame it. It is not the headline it became.
Medi-Cal (California), Eli Lilly (LLY): Two items that circulated this week and did not change anything. A September 13 guest column argued that California's governor should restore Medi-Cal coverage of obesity medicines; the coverage was removed in the state budget enacted earlier in 2026 with a projected saving above 600 million dollars by 2029, and no restoration has been announced. The column is advocacy, not an event. Separately, coverage of Eli Lilly fighting a black market for its next obesity drug refers to the retatrutide grey market this log recorded on August 25; we found no new dated development in the September 8 to 14 window. Both are recorded here so that their reappearance is not mistaken for news.